Guided Therapeutics (GTHP) Net Cash Flow Growth (5y) (2016 - 2025)
Guided Therapeutics (GTHP) Net Cash Flow Growth (5y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.94 Bn | 176.64 Bn | 6.27 Bn |
| 2 | Stryker | 128.78 Bn | 125.90 Bn | 3.81 Bn |
| 3 | Medtronic | 109.01 Bn | 99.79 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.59 Bn | 67.13 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.66 Bn | 43.99 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn |
| 7 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.93 Bn | 26.36 Bn | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43.00% |
| Sep 30, 2025 | 12.11% |
| Jun 30, 2025 | -37.65% |
| Mar 31, 2025 | 20.83% |
| Dec 31, 2024 | -26.41% |
| Jun 30, 2024 | -95.19% |
| Mar 31, 2024 | -92.35% |
| Dec 31, 2023 | -14.87% |
| Sep 30, 2023 | -88.22% |
| Jun 30, 2023 | -68.75% |
| Mar 31, 2023 | -52.86% |
| Dec 31, 2022 | -39.38% |
| Sep 30, 2022 | 102.51% |
| Jun 30, 2022 | -108.53% |
| Mar 31, 2022 | 52.72% |
| Dec 31, 2021 | 59.12% |
| Sep 30, 2021 | -58.29% |
| Jun 30, 2021 | -20.97% |
| Mar 31, 2021 | 1.76% |
| Dec 31, 2020 | -26.68% |